386 related articles for article (PubMed ID: 28386677)
21. Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation.
Iorgulescu JB; Van Ziffle J; Stevers M; Grenert JP; Bastian BC; Chavez L; Stichel D; Buchhalter I; Samuel D; Nicolaides T; Banerjee A; Mueller S; Gupta N; Tihan T; Bollen AW; Northcott PA; Kool M; Pfister S; Korshunov A; Perry A; Solomon DA
Acta Neuropathol; 2018 Apr; 135(4):635-638. PubMed ID: 29435664
[No Abstract] [Full Text] [Related]
22. Molecular Subgrouping of Medulloblastoma: Impact Upon Research and Clinical Practice.
Gupta T; Shirsat N; Jalali R
Curr Pediatr Rev; 2015; 11(2):106-19. PubMed ID: 26133181
[TBL] [Abstract][Full Text] [Related]
23. Medulloblastoma comprises four distinct molecular variants.
Northcott PA; Korshunov A; Witt H; Hielscher T; Eberhart CG; Mack S; Bouffet E; Clifford SC; Hawkins CE; French P; Rutka JT; Pfister S; Taylor MD
J Clin Oncol; 2011 Apr; 29(11):1408-14. PubMed ID: 20823417
[TBL] [Abstract][Full Text] [Related]
24. DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies.
Schwalbe EC; Williamson D; Lindsey JC; Hamilton D; Ryan SL; Megahed H; Garami M; Hauser P; Dembowska-Baginska B; Perek D; Northcott PA; Taylor MD; Taylor RE; Ellison DW; Bailey S; Clifford SC
Acta Neuropathol; 2013 Mar; 125(3):359-71. PubMed ID: 23291781
[TBL] [Abstract][Full Text] [Related]
25. Desmoplastic/nodular medulloblastomas (DNMB) and medulloblastomas with extensive nodularity (MBEN) disclose similar epigenetic signatures but different transcriptional profiles.
Korshunov A; Sahm F; Okonechnikov K; Ryzhova M; Stichel D; Schrimpf D; Casalini B; Sievers P; Meyer J; Zheludkova O; Golanov A; Lichter P; Jones DTW; Pfister SM; Kool M; von Deimling A
Acta Neuropathol; 2019 Jun; 137(6):1003-1015. PubMed ID: 30826918
[TBL] [Abstract][Full Text] [Related]
26. Medulloblastoma in the age of molecular subgroups: a review.
Juraschka K; Taylor MD
J Neurosurg Pediatr; 2019 Oct; 24(4):353-363. PubMed ID: 31574483
[TBL] [Abstract][Full Text] [Related]
27. Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis.
Clifford SC; Lusher ME; Lindsey JC; Langdon JA; Gilbertson RJ; Straughton D; Ellison DW
Cell Cycle; 2006 Nov; 5(22):2666-70. PubMed ID: 17172831
[TBL] [Abstract][Full Text] [Related]
28. Prognostic classification of pediatric medulloblastoma based on chromosome 17p loss, expression of MYCC and MYCN, and Wnt pathway activation.
Park AK; Lee SJ; Phi JH; Wang KC; Kim DG; Cho BK; Haberler C; Fattet S; Dufour C; Puget S; Sainte-Rose C; Bourdeaut F; Grill J; Delattre O; Kim SK; Park WY
Neuro Oncol; 2012 Feb; 14(2):203-14. PubMed ID: 22090452
[TBL] [Abstract][Full Text] [Related]
29. Expression of GNAS, TP53, and PTEN Improves the Patient Prognostication in Sonic Hedgehog (SHH) Medulloblastoma Subgroup.
da Silva LS; Mançano BM; de Paula FE; Dos Reis MB; de Almeida GC; Matsushita M; Junior CA; Evangelista AF; Saggioro F; Serafini LN; Stavale JN; Malheiros SMF; Lima M; Hajj GNM; de Lima MA; Taylor MD; Leal LF; Reis RM
J Mol Diagn; 2020 Jul; 22(7):957-966. PubMed ID: 32380172
[TBL] [Abstract][Full Text] [Related]
30. Subgroup-specific alternative splicing in medulloblastoma.
Dubuc AM; Morrissy AS; Kloosterhof NK; Northcott PA; Yu EP; Shih D; Peacock J; Grajkowska W; van Meter T; Eberhart CG; Pfister S; Marra MA; Weiss WA; Scherer SW; Rutka JT; French PJ; Taylor MD
Acta Neuropathol; 2012 Apr; 123(4):485-499. PubMed ID: 22358458
[TBL] [Abstract][Full Text] [Related]
31. Molecular Stratification of Medulloblastoma: Clinical Outcomes and Therapeutic Interventions.
Sursal T; Ronecker JS; Dicpinigaitis AJ; Mohan AL; Tobias ME; Gandhi CD; Jhanwar-Uniyal M
Anticancer Res; 2022 May; 42(5):2225-2239. PubMed ID: 35489737
[TBL] [Abstract][Full Text] [Related]
32. [Subtypes of medulloblastomas: distinct cellular origins].
Bourdeaut F; Pouponnot C; Ayrault O
Med Sci (Paris); 2012 Oct; 28(10):805-9. PubMed ID: 23067406
[No Abstract] [Full Text] [Related]
33. Comparison of Clinical and Molecular Wnt and SHH Subgroups in Medulloblastoma Tumor Cases.
Kaya IS; Aksoy S; Mutlu M; Tekin C; Taskapilioglu MO; Tunca B; Civan MN; Ocak PE; Kocaeli H; Bekar A; Egeli U; Cecener G; Tolunay S
Turk Neurosurg; 2021; 31(4):554-565. PubMed ID: 33978203
[TBL] [Abstract][Full Text] [Related]
34. Elevated Kir2.1/nuclear N2ICD defines a highly malignant subtype of non-WNT/SHH medulloblastomas.
Wang YX; Wu H; Ren Y; Lv S; Ji C; Xiang D; Zhang M; Lu H; Fu W; Liu Q; Yan Z; Ma Q; Miao J; Cai R; Lan X; Wu B; Wang W; Liu Y; Wang DZ; Cao M; He Z; Shi Y; Ping Y; Yao X; Zhang X; Zhang P; Wang JM; Wang Y; Cui Y; Bian XW
Signal Transduct Target Ther; 2022 Mar; 7(1):72. PubMed ID: 35273141
[TBL] [Abstract][Full Text] [Related]
35. Wnt/β-catenin signaling inhibits the Shh pathway and impairs tumor growth in Shh-dependent medulloblastoma.
Pöschl J; Bartels M; Ohli J; Bianchi E; Kuteykin-Teplyakov K; Grammel D; Ahlfeld J; Schüller U
Acta Neuropathol; 2014 Apr; 127(4):605-7. PubMed ID: 24531885
[No Abstract] [Full Text] [Related]
36. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations.
Pugh TJ; Weeraratne SD; Archer TC; Pomeranz Krummel DA; Auclair D; Bochicchio J; Carneiro MO; Carter SL; Cibulskis K; Erlich RL; Greulich H; Lawrence MS; Lennon NJ; McKenna A; Meldrim J; Ramos AH; Ross MG; Russ C; Shefler E; Sivachenko A; Sogoloff B; Stojanov P; Tamayo P; Mesirov JP; Amani V; Teider N; Sengupta S; Francois JP; Northcott PA; Taylor MD; Yu F; Crabtree GR; Kautzman AG; Gabriel SB; Getz G; Jäger N; Jones DT; Lichter P; Pfister SM; Roberts TM; Meyerson M; Pomeroy SL; Cho YJ
Nature; 2012 Aug; 488(7409):106-10. PubMed ID: 22820256
[TBL] [Abstract][Full Text] [Related]
37. Advanced MRI Findings in Medulloblastomas: Relationship to Genetic Subtypes, Histopathology, and Immunohistochemistry.
Reis J; Stahl R; Zimmermann H; Ruf V; Thon N; Kunz M; Liebig T; Forbrig R
J Neuroimaging; 2021 Mar; 31(2):306-316. PubMed ID: 33465267
[TBL] [Abstract][Full Text] [Related]
38. Identification of Two Protein-Signaling States Delineating Transcriptionally Heterogeneous Human Medulloblastoma.
Zomerman WW; Plasschaert SLA; Conroy S; Scherpen FJ; Meeuwsen-de Boer TGJ; Lourens HJ; Guerrero Llobet S; Smit MJ; Slagter-Menkema L; Seitz A; Gidding CEM; Hulleman E; Wesseling P; Meijer L; van Kempen LC; van den Berg A; Warmerdam DO; Kruyt FAE; Foijer F; van Vugt MATM; den Dunnen WFA; Hoving EW; Guryev V; de Bont ESJM; Bruggeman SWM
Cell Rep; 2018 Mar; 22(12):3206-3216. PubMed ID: 29562177
[TBL] [Abstract][Full Text] [Related]
39. TERT promoter mutation and aberrant hypermethylation are associated with elevated expression in medulloblastoma and characterise the majority of non-infant SHH subgroup tumours.
Lindsey JC; Schwalbe EC; Potluri S; Bailey S; Williamson D; Clifford SC
Acta Neuropathol; 2014 Feb; 127(2):307-9. PubMed ID: 24337442
[No Abstract] [Full Text] [Related]
40. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas.
Kool M; Korshunov A; Remke M; Jones DT; Schlanstein M; Northcott PA; Cho YJ; Koster J; Schouten-van Meeteren A; van Vuurden D; Clifford SC; Pietsch T; von Bueren AO; Rutkowski S; McCabe M; Collins VP; Bäcklund ML; Haberler C; Bourdeaut F; Delattre O; Doz F; Ellison DW; Gilbertson RJ; Pomeroy SL; Taylor MD; Lichter P; Pfister SM
Acta Neuropathol; 2012 Apr; 123(4):473-84. PubMed ID: 22358457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
